Quanterix Corporation QTRX R2K
Quanterix Corporation, a life sciences company in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assays include all components required to run enzyme-based immunoassay, such as beads, capture and detector reagents, and enzyme reagents and substrate; and replacement parts, reagents, and antibodies. In addition, the company offers contract research and clinical laboratory testing services, including research and clinical trial testing, and lucent diagnostic services. The company primarily operates in the areas of neurology, oncology and immunology, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct field sale, support organizations, and sales force and distributors. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.
READ MORE ›Market & Price
Valuation
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Growth (CAGR)
PROS
No notable strengths flagged.
CONS
- Earnings shrank at -2.5% CAGR over 5 years.
- Trading 62.0% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | QTRX Quanterix Corporation R2K | 3.06 | - | $144.14M | - | -31.92% | -34.81% | 9.73% | -2.54% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Quarterly Results
Figures in USD.
| Metric | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | 7.52M | 8.64M | 10.59M | 10.88M | 12.34M | 13.54M | 14.94M | 15.92M | 15.73M | 13.13M | 31.39M | 26.13M | 27.21M | 25.37M | 27.69M | 29.55M | 23.50M | 26.65M | 28.46M | 31.03M | 31.56M | 32.07M | 34.38M | 35.81M | - | 30.33M | 24.45M | 40.15M | 43.78M | 36.41M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 15.49M | 13.18M | 23.03M | 23.82M | 20.85M |
| Gross Profit | - | - | 2.56M | - | 3.17M | 3.97M | 5.59M | 5.21M | 6.01M | 6.93M | 7.03M | 6.87M | 6.81M | 5.21M | 21.11M | 15.05M | 16.35M | 13.87M | 15.24M | 14.56M | 8.71M | 10.94M | 16.93M | 19.14M | 19.41M | 18.55M | 22.23M | 20.15M | - | 14.84M | 11.28M | 17.12M | 19.96M | 15.57M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 41.20M | 40.71M | 47.27M | 43.83M | 37.09M |
| Operating Income | -6.06M | -6.47M | -6.39M | -7.09M | -7.16M | -7.31M | -7.66M | -9.41M | -9.36M | -10.51M | -10.24M | -11.49M | -11.73M | -12.20M | 2.28M | -9.93M | -9.79M | -13.67M | -15.23M | -18.19M | -24.96M | -36.60M | -9.42M | -9.56M | -12.81M | -15.16M | -10.94M | -11.75M | - | -26.37M | -29.43M | -30.15M | -23.87M | -21.53M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -24.18M | -26.58M | -25.57M | -14.56M | -15.92M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -23.42M | -30.09M | -36.00M | -22.77M | -17.55M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -2.91M | -73.00K | -2.48M | 345.00K | -7.00K |
| Net Income | -6.39M | -6.63M | -6.61M | -7.38M | -7.20M | -7.34M | -7.66M | -9.33M | -9.40M | -10.56M | -9.87M | -10.96M | -11.61M | -12.30M | 2.20M | -9.82M | -10.10M | -11.90M | -15.66M | -18.15M | -24.90M | -35.06M | -7.27M | -5.55M | -6.72M | -11.16M | -7.39M | -8.35M | - | -20.50M | -30.01M | -33.52M | -23.12M | -17.54M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | -0.37 | - | -0.41 | -0.43 | 0.07 | -0.31 | -0.29 | -0.33 | -0.43 | -0.49 | -0.67 | -0.95 | -0.16 | -0.16 | -0.18 | -0.29 | -0.19 | -0.22 | - | -0.53 | -0.77 | -0.73 | -0.49 | -0.37 |
| R&D Expense | 4.25M | 3.90M | 4.22M | 3.93M | 3.64M | 3.71M | 4.41M | 4.04M | 3.85M | 4.02M | 3.92M | 4.40M | 4.27M | 4.31M | 5.38M | 6.22M | 6.68M | 6.75M | 6.81M | 7.03M | 6.62M | 6.63M | 4.72M | 5.95M | 7.74M | 6.74M | 8.17M | 8.10M | - | 10.04M | 9.08M | 8.01M | - | 7.32M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | 22.87M | 37.63M | 56.73M | 86.38M | - | 104.95M | 121.14M | 135.44M | 138.65M |
| Cost of Revenue | - | - | - | - | - | - | 60.16M | 48.14M | 54.32M | 73.94M |
| Gross Profit | 7.75M | 9.99M | 17.95M | 26.84M | 48.18M | - | 44.79M | 73.00M | 81.12M | 64.72M |
| Operating Expenses | - | - | - | - | - | - | 119.50M | 117.66M | 133.74M | 174.53M |
| Operating Income | -21.71M | -26.00M | -31.55M | -41.60M | -31.58M | - | -74.71M | -44.66M | -52.62M | -109.81M |
| EBITDA | - | - | - | - | - | - | -68.58M | -36.37M | -44.26M | -90.89M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | -99.41M | -27.64M | -38.10M | -112.27M |
| Tax Provision | - | - | - | - | - | - | 164.00K | 719.00K | 434.00K | -5.12M |
| Net Income | -23.17M | -27.02M | -31.54M | -40.80M | -31.53M | - | -99.57M | -28.35M | -38.53M | -107.15M |
| Diluted EPS | - | - | - | -1.63 | -1.07 | - | -2.61 | -0.75 | -1.00 | -2.51 |
| R&D Expense | 16.99M | 16.30M | 15.80M | 16.19M | 20.17M | 27.98M | 26.81M | 26.06M | 31.08M | 35.92M |
Compounded Sales Growth
| 5 Years: | 9.73% |
| 1 Year: | 20.10% |
Compounded Profit Growth
| 5 Years: | -2.54% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | -41.15% |
| 6 Months: | -57.68% |
| 3 Months: | -53.28% |
| 1 Month: | +0.33% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 91.78M | 67.61M | 169.95M | 271.05M | - | 433.58M | 428.57M | 406.53M | 418.77M |
| Current Assets | - | - | - | - | - | - | - | 381.52M | 382.10M | 363.59M | 212.26M |
| Cash & Equivalents | - | - | 79.68M | 44.43M | 109.16M | 181.58M | - | 338.74M | 174.42M | 56.71M | 29.84M |
| Inventory | - | - | - | - | - | - | - | 16.96M | 26.12M | 32.77M | 54.76M |
| Receivables | - | - | - | - | - | - | - | 19.02M | 25.41M | 32.14M | 29.97M |
| Total Liabilities | - | - | 25.91M | 26.55M | 41.29M | 64.92M | - | 75.65M | 78.61M | 76.50M | 123.04M |
| Current Liabilities | - | - | 19.71M | 18.12M | 19.83M | 39.80M | - | 31.35M | 38.98M | 42.01M | 74.76M |
| Long Term Debt | - | - | 4.35M | 7.62M | 7.59M | - | - | - | - | - | - |
| Total Debt | - | - | - | - | - | - | - | 44.10M | 41.46M | 37.37M | 37.24M |
| Total Equity | -88.64M | -115.11M | 65.87M | 41.06M | 128.66M | 206.12M | - | 357.93M | 349.96M | 330.04M | 295.73M |
| Shares Outstanding | - | - | - | - | - | - | - | 37.28M | 38.01M | 38.54M | 46.74M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -17.74M | -22.11M | -28.72M | -26.19M | -23.36M | - | -48.61M | -18.85M | -35.16M | -77.24M |
| Investing Cash Flow | -826.00K | -1.13M | -5.45M | -25.38M | -626.00K | - | -11.09M | -148.45M | -82.27M | 50.23M |
| Financing Cash Flow | 45.92M | 73.25M | -78.00K | 116.20M | 96.24M | - | 2.31M | 2.69M | 456.00K | -708.00K |
| Capital Expenditure | -526.00K | -1.13M | -1.52M | -10.85M | -3.93M | - | -11.61M | -3.84M | -3.37M | -2.61M |
| Free Cash Flow | -18.27M | -23.24M | -30.24M | -37.03M | -27.30M | - | -60.23M | -22.69M | -38.53M | -79.85M |
| Net Change in Cash | - | - | - | - | - | - | -57.39M | -164.61M | -116.97M | -27.71M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | 43.7% | 47.7% | 47.3% | 55.8% | - | 42.7% | 60.3% | 59.9% | 46.7% |
| Operating Margin % | - | -113.7% | -83.8% | -73.3% | -36.6% | - | -71.2% | -36.9% | -38.8% | -79.2% |
| Net Margin % | - | -118.1% | -83.8% | -71.9% | -36.5% | - | -94.9% | -23.4% | -28.4% | -77.3% |
| ROE % | 20.1% | -41.0% | -76.8% | -31.7% | -15.3% | - | -27.8% | -8.1% | -11.7% | -36.2% |
| ROCE % | - | -36.1% | -63.8% | -27.7% | -13.7% | - | -18.6% | -11.5% | -14.4% | -31.9% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Ameriprise Financial, Inc. | 7.52% | 3.54M | $10.84M |
| 2 | Blackrock Inc. | 6.96% | 3.28M | $10.03M |
| 3 | Portolan Capital Management, LLC | 6.25% | 2.95M | $9.01M |
| 4 | Blue Water Life Science Advisors, Lp | 4.55% | 2.14M | $6.55M |
| 5 | William Blair Investment Management, LLC | 4.42% | 2.08M | $6.38M |
| 6 | Invenomic Capital Management, LP | 4.10% | 1.93M | $5.91M |
| 7 | Vanguard Capital Management LLC | 3.79% | 1.78M | $5.46M |
| 8 | Levin Capital Strategies, LP | 3.11% | 1.46M | $4.48M |
| 9 | First Eagle Investment Management, LLC | 2.76% | 1.30M | $3.98M |
| 10 | Geode Capital Management, LLC | 2.11% | 994.76K | $3.04M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for QTRX